NCT02420860View on ClinicalTrials.gov

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

April 14, 2015

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma
Interventions
BIOLOGICAL

Elotuzumab

Given IV

DRUG

Lenalidomide

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER